As AI adoption accelerates across healthcare, ensuring transparency, reproducibility, and scientific rigour remains essential. ICON discusses how organisations can apply AI and machine learning to real-world oncology dat...

Because patients can’t wait, every rare disease development decision matters. Meet ICON at World Orphan Drug Congress Europe, booth \#313, to discuss how our integrated development and regulatory strategy, patient advoca...

Meet with ICON's Clinical Pharmacology team at the 2026 ACCP Annual Meeting and discover new insights from our poster, "siRNA oligonucleotide metabolites: From nuclease processing to pharmacodynamic and adverse events." ...

Join ICON's presentation at WorldCDx on 8 October to explore the common pitfalls that can derail precision medicine initiatives and learn practical approaches for building robust, globally deployable biomarker and compan...

How can medtech companies reduce packaging while maintaining protection, functionality and compliance? In the fourth and final article in MedTech Insight’s PPWR series, ICON's SMEs discuss why packaging minimisation is ...

Blood‑based biomarkers are reshaping Alzheimer’s trials by enabling earlier, cheaper identification. Could these enrolment strategies translate to other slow‑progressing diseases? ICON experts share their insight in the ...

For global clinical trials, localisation, translation availability and linguistic validation can all affect when and how a clinical outcome assessment can be implemented across countries. Yet these considerations are o...

We're heading to Boston for The MedTech Conference, 18 – 21 October. Whether you're developing a medical device, diagnostic, digital health technology, wearable, or combination product, successful development requires m...

Great teams are built through shared experiences. Our Beijing colleagues recently stepped away from their desks to enjoy a day of team-building activities followed by a group dinner. The event provided a fantastic oppor...

ICON is proud to be the Platinum Sponsor of the TOPRA Symposium 2026, Europe’s premier conference for healthcare regulatory affairs. Taking place at the Royal Jaarbeurs in Utrecht from 19 to 21 October, the Symposium wi...

Eligibility criteria that successfully identify high-risk patients in a clinical trial may be impossible to replicate in routine practice. For MASLD developers, regulatory success and commercial viability are not the sam...

The pressure to make confident development decisions earlier has never been greater. Discover how innovative early phase trial designs, patient engagement strategies, and biomarker insights are helping sponsors navigate ...